Search

Introduction: Over the past 20 years, palliative care in the United States has grown significantly. Yet, access to and/or engagement with palliative care for minoritized persons with serious illness remains limited. In addition, the focus of palliative and end-of-life care research has not historically focused on equity-informed intervention development that collaborates directly with minoritized populations. Equity-informed interventions within palliative and end-of-life care research have the potential to champion collaborations with persons with serious illness and their families to mitigate health inequities. The purpose of this scoping review was to examine and describe the literature on the approaches used in the design and development of palliative and end-of-life care interventions with minoritized populations with serious illness., Methods: The Joanna Briggs Institute methodology for scoping reviews was followed for tracking and reporting purposes. Included articles were described quantitatively and analyzed qualitatively with content analysis., Results: Thirty-seven articles met the inclusion criteria: eight used quantitative methods, eight used qualitative methods, ten reported a community-based participatory research method, nine used mixed-methods, and two had research designs that could not be determined. The qualitative analysis revealed three themes: (1) stakeholder involvement and feedback, (2) intervention focus, and (3) target intervention population (population vs healthcare clinician)., Conclusions: Using an equity-informed research approach is vital to improve palliative and end-of-life care interventions for minoritized communities with serious illness. There is also a need for more robust publishing guidelines related to community-based participatory research methods to ensure publication consistency among research teams that employ this complex research method., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Self-reported food allergies (FAs) affect approximately 8% of the US pediatric and approximately 10% of the adult population, which reflects potentially disproportionate increases among ethnically and racially minoritized groups. Multiple gaps and unmet needs exist regarding FA disparities. There is reported evidence of disparities in FA outcomes, and the FA burden may also be disproportionate in low-income families. Low family income has been associated with higher emergency care spending and insecure access to allergen-free food. Pharmacoinequity arises in part as a result of structural racism still experienced by historically marginalized populations today. Historically redlined communities continue to experience greater rates of neighborhood-level air pollution and indoor allergen exposure, lack of transportation to medical appointments, poverty, and lower prescription rates of necessary medications. Clinical research needs racially and ethnically diverse participation to ensure generalizability of research findings and equitable access to medical advances, but race reporting in clinical trials has been historically poor. Addressing health disparities in FA is a priority of clinical care, with professional organizations such as the American Academy of Allergy, Asthma & Immunology having a prominent role to play in mitigating the challenges faced by these individuals. In this position statement we recommend some key steps to address this important issue., Competing Interests: Disclosure statement Disclosure of potential conflict of interest: A. Anagnostou reports institutional funding from Aimmune Therapeutics and Novartis; is an advisory board member for Genentech, Novartis, Bryn, and Ready Set Food; and receives consultation/speaker fees from ALK-Abelló, Adelphi, Aimmune Therapeutics, MJH, FARE, Genentech, EPG Health, and Medscape. J. Wang receives research support paid to institution from the National Institute of Allergy and Infectious Diseases, Aimmune Therapeutics, DBV Technologies, and Siolta; receives consultancy fees from ALK-Abelló and Novartis; and receives royalty payments from UpToDate. R. S. Chinthrajah receives grant support from the Consortium for Food Allergy Research, the National Institute of Allergy and Infectious Disease, FARE, and Aimmune Therapeutics; and is an advisory board member for Alladapt Immunotherapeutics, Novartis, Allergenis, Intrommune Therapeutics, Phylaxis, and Genentech. R. Gupta receives research grant support from the National Institutes of Health, FARE, the Melchiorre Family Foundation, the Sunshine Charitable Foundation, the Walder Foundation, the UnitedHealth Group, Thermo Fisher Scientific, and Genentech; serves as a medical consultant/advisor for Genentech, Novartis, Aimmune Therapeutics, Allergenis LLC, and FARE; and has ownership interest in Yobee Care, Inc. C. M. Davis reports research grant support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, CBV Technologies, Regeneron Pharmaceuticals, Takeda Pharmaceuticals, Allergenis, and Novartis; serves on the editorial board of the Journal of Allergy and Clinical Immunology: In Practice; serves on the board of directors of the American Academy of Allergy, Asthma & Immunology as Secretary-Treasurer; is past president of the Texas Allergy, Asthma, and Immunology Society; and has received honoraria from MJH Life Sciences. C. Parrish receives research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals, and DBV Technologies (all funds to institution); and receives speaking/consulting fees from Sanofi, Takeda Pharmaceuticals, and Magellan Rx. M. Groetch reports royalties from UpToDate and the Academy of Nutrition and Dietetics; receives consulting fees from Food Allergy Research Education; serves on the medical advisory board of IFPIES; serves as a senior advisor for FARE; serves as a health sciences advisor for APFED; serves on the editorial board of the Journal of Food Allergy; and has no commercial interests to disclose. J. Shroba was an employee at Children’s Mercy; is now employed at DBV Technologies; and served on the advisory board for Thermo Fisher Scientific and Genentech. M. Shaker is a member and cochair of the Joint Task Force on Practice Parameters; serves on the editorial board of the Journal of Allergy and Clinical Immunology: In Practice; is an associate editor for the Annals of Allergy, Asthma & Immunology; serves on the board of directors of the American Academy of Allergy, Asthma & Immunology (views expressed are his own); and has participated in research that has received funding from DBV Technologies. M. Greenhawt is a consultant for Aquestive; is a member of physician/medical advisory boards for DBV Technologies, Nutricia, Novartis, Aquestive, Allergy Therapeutics, AstraZeneca, ALK-Abelló, Bryn, Genentech, and Prota; is a speaker for Genentech; is an unpaid member of the Scientific Advisory Council for the National Peanut Board and the Medical Advisory Board of the International Food Protein Induced Enterocolitis Syndrome Association; is a member of the Brighton Collaboration Criteria Vaccine Anaphylaxis 2.0 Working Group; is the senior associate editor for the Annals of Allergy, Asthma & Immunology; is a member of the Joint Task Force on Allergy Practice Parameters; and has received honoraria for lectures from ImSci, Red Nucleus, Medscape, Paradigm Medical Communications, and multiple state/local allergy societies., (Copyright © 2024 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)

Health disparities persist among minoritized populations. A diverse clinician workforce may help address these disparities and improve patient outcomes; however, diversity in the critical are workforce (particularly among women and those historically underrepresented in medicine (URiM)) is lacking. This review describes factors contributing to low respresentation of women and URiM in critical care medicine, and proposes strategies to overcome those barriers., Competing Interests: Disclosure The authors have nothing to disclose., (Published by Elsevier Inc.)